A Double-Blind Efficacy and Safety Study of Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia

Trial Profile

A Double-Blind Efficacy and Safety Study of Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia

Discontinued
Phase of Trial: Phase III

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs Evacetrapib (Primary) ; Atorvastatin; Ezetimibe
  • Indications Hypercholesterolaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 03 Aug 2017 Primary endpoint (Percent Change from Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C) Measured by Beta Quantification, Evacetrapib vs Ezetimibe) has not been met as per results published in the Circulation Journal
    • 03 Aug 2017 Primary endpoint (Percent Change from Baseline to Week 12 in Low-Density Lipoprotein Cholesterol (LDL-C) Measured by Beta Quantification, Evacetrapib vs placebo) has been met as per results published in the Circulation Journal.
    • 03 Aug 2017 Results published in the Circulation Journal
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top